- Insilico Medicine’s AI-discovered drug rentosertib reduced patients’ biological age by up to six years four weeks after initial dosing, as measured by six independent aging clocks developed by teams at Insilico, Harvard, Peking University, and others — while placebo patients showed little to no change — according to a study published Monday in Nature Biotechnology.
- The drug was designed entirely by AI: Insilico first used an AI tool to scan large biological datasets and identify the target (TNIK kinase) as implicated in aging, then used a second AI system to virtually screen molecules and optimize the drug candidate — a fully AI-driven pipeline from target discovery through drug design.
- Rentosertib is currently in a late-stage clinical trial in China for idiopathic pulmonary fibrosis (IPF), an incurable progressive lung disease — and Insilico CEO Alex Zhavoronkov said the aging results will open the door for doctors to prescribe the drug for aging-related conditions once it gains approval for IPF, even before any regulatory approval specifically for aging exists.
- Insilico shares jumped as much as 10% Tuesday, the largest single-day gain since August 25, and the company plans to run similar aging-clock analyses on at least half its broader drug pipeline — a move that could reframe the entire company’s commercial narrative from rare-disease biotech to longevity platform.
What Happened?
Insilico Medicine published a sub-study of its Phase 2 IPF trial in Nature Biotechnology showing that rentosertib reversed biological aging markers in 42 patients. Biological age — as distinct from chronological age — measures how well cells and tissues are functioning, and the six aging clocks used in this study each apply different molecular methods to estimate it. Patients receiving rentosertib saw biological age drop by as much as six years after four weeks of treatment, though the benefit narrowed at later time points. The study represents the first published evidence from a clinical trial that a novel AI-designed drug can measurably reverse aging biomarkers in humans, rather than simply slowing their progression.
Why It Matters?
This is a significant commercial and scientific inflection point for both Insilico and the broader AI drug discovery sector. Scientifically, using aging clocks as a secondary endpoint in a disease-focused trial creates a template for the industry: rather than waiting decades for longevity endpoints, companies can now demonstrate anti-aging effects in shorter disease trials and use those results to unlock off-label prescription potential. Commercially, Zhavoronkov’s explicit suggestion that approval for IPF will enable prescribing for aging is a direct roadmap for expanding rentosertib’s addressable market far beyond IPF’s roughly 100,000 US patients. With GLP-1 drugs having already proven that therapeutics can have multi-indication blockbuster potential far beyond their initial indication, investors are right to pay attention to a drug that could be prescribed for one of the largest and most affluent markets in medicine: healthy aging.
What’s Next?
The late-stage China IPF trial is the immediate regulatory catalyst — approval there would give Insilico its first commercially approved drug and trigger the off-label aging narrative Zhavoronkov is already telegraphing. The company will need to run larger studies to confirm whether the aging clock reversals are durable beyond four weeks and translate into clinical outcomes (longer survival, lower disease burden) — the current 42-patient dataset is too small to draw those conclusions. If rentosertib gains approval and aging-clock analysis becomes standard in biotech trials, it could reshape how pharma companies pitch their pipelines to investors, with “biological age reduction” becoming as commercially meaningful as traditional efficacy endpoints.
Source: Bloomberg
